फा.सं. F. No.50014/03/2020-CDN

भारत सरकार / Government of India

रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals & Fertilizers

औषध विभाग / Department of Pharmaceuticals

Shastri Bhawan, New Delhi Dated: 13th May, 2022

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of April, 2022-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of April, 2022 for information.

Salar

(Shamim Uddin Ansari) Under Secretary to the Govt. of India Tel. 011-2806 3104

To,

- 1. All members of Council of Ministers.
- 2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
- 3. The Principal information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

- 1. Secretaries to the Govt. of India, All Ministries/Department.
- 2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
- 3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
- 4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
- 5. PS to Prime Minister of India, South Block, New Delhi-110004.
- 6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
- 7. Sr. PPS to Secretary (Pharma).
- 8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

1. Important policy decisions taken and major achievements during the month of April 2022:

A. Medical Devices:

(i). A meeting was held on 11.04.2022 at 11 AM on the measures to be taken towards strengthening of testing infrastructure to enable smoother transition to licensing for Medical Devices under the chairpersonship of Secretary, Department of Pharmaceuticals. Pursuant to the decision taken in the meeting, a Task Force under the Standing Forum of Medical Devices Associations was constituted vide 31026/24/2022-MD dated 13.04.2022 to prepare the road map for mapping and augmenting the laboratory resources required under Medical Device Regulations. The committee will submit the report / recommendations to the Department of Pharmaceuticals within 30 days.

B. National Institutes of Pharmaceutical Education & Research (NIPERs):

- (i). NIPER Mohali has been ranked 44th in the world, 7th in the Asia and **first in the country** as per QS (Quacquarelli Symonds) rankings for the year 2022, under the subject category 'Pharmacy and Pharmacology'
- (ii). Organized one-day online training for scientists/faculty of various NIPERs on IPR/ patent filing and related issues through O/o Controller General of Patents, Designs & Trade Marks (CGPDTM), DPIIT, Ministry of Commerce & Industry - Govt. of India on 8th April 2022, which was attended by total 23 faculty members.
- (iii). During the months of April, 2022 NIPERs have organized 6 Seminars, 8 Workshops/Training and 14 other events. The important events organized by NIPERs include:
 - (a) Developing indigenous products through deep research and innovation by NIPER Guwahati on 1st April 2022.
 - (b) Health Camp at Hajong Bori, Chandrapur block (T), Kamarup district by NIPER Guwahati on 7th April 2022.
 - (c) "Application of Quantum Chemistry and Molecular Modelling Methods in Drug Discovery" Hands-on Workshop on Gaussian 16 & Gauss View 06 by NIPER Guwahati from 8th to 9th April 2022.
 - (d) National Level Seminar on Intellectual Property rights (IPR) by NIPER Guwahati on 28th April 2022.
 - (e) DBT Sponsored Skill Vigyan Training Programme on Module I: Quality Management system-In charge by NIPER Mohali from 14th March, 2022 to 5th April, 2022.
 - (f) DBT Sponsored Skill Vigyan Training Programme on Module II: Production/ Manufacturing Chemist by NIPER Mohali from 14th March, 2022 to 5th April, 2022.
 - (g) Short term certification Course- Pharmaceutical Industrial Training by NIPER Mohali from 20th April, 2022 to 6th May, 2022.
 - (h) BioBetter- The Next Frontier of Biopharmaceuticals by NIPER Mohali on 1st April, 2022.
 - (i) Standardized Jamun extract as potential anti-cancer herbal formulation by NIPER Mohali on 8th April, 2022.
 - (j) Recent Development in the Synthesis of Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) by NIPER Mohali on 29th April, 2022.

- (k) Hand on practical training on High performance liquid chromatography (HPLC) by NIPER Mohali from 18th April, 2022 to 22nd April, 2022.
- (1) Spandan-2022 Events (Sports and Cultural Meet) by NIPER Mohali from 23rd and 24th April, 2022.
- (m)DP Workshop on "Molecular Docking, Virtual Screening and Computational Biology" by NIPER Hyderabad from 28th March, 2022 to 8th April, 2022.
- (n) Hands-on Experience on Instruments & Techniques for 3D Printer, Cell culture & Nanotechnology based Drug Delivery by NIPER Hyderabad from 5th April, 2022 to 7th April, 2022.
- (o) Awareness Related to Intellectual Property Rights IPRs organized by Patent Office, Kolkata under DPIIT, GoI with NIPER Hyderabad by NIPER Hyderabad on 8th April, 2022.
- (p) International Conference on Nextgen Therapeutics & Diagnostics by NIPER Hyderabad from 20th April, 2022 to 22nd April, 2022.
- (q) First CEOs/ MDs Roundtable Meet by NIPER Hyderabad on 29th April, 2022. Two days' workshop on Quality by Design (QbD) to analytical method development and product development by NIPER Hajipur from 5th April, 2022 and 6th April, 2022.
- (r) Invited Lecture on Integrative genomics approaches identify Alzheimer's disease specific alterations by NIPER Hajipur on 20th April, 2022.
- (s) Webinar on Components of Protocol writing for Regulatory Randomized Clinical Trails by NIPER Hajipur on 25th April, 2022.
- (t) Sports Week by NIPER Ahmedabad from 28th March, 2022 and 10th April, 2022.
- (u) Seminar on Future Leaders and Entrepreneurs by NIPER Ahmedabad on 12th April, 2022.
- (v) Expert Lecture Series-I on 'Emerging trends in Neurological Disorders by NIPER Ahmedabad from 20th April, 2022 and 22nd April, 2022.
- (w) Feliz Fiesta 2022 culture event by NIPER Ahmedabad on 28th April, 2022.
- (x) Webinar "Role of Natural Products in Drug Discovery and Development" by NIPER Ahmedabad on 29th April, 2022.
- (y) Meeting to review on Health products by NIPER Kolkata on 13th April, 2022.
- (iv). Out of 78 Research Papers published during the current financial year, 78 papers have been published in the month April, 2022.
- (v) Out of 2 Patents filed during the current financial year, 2 patent have been filed during the April, 2022.

C. National Pharmaceutical Pricing Authority (NPPA):

- (i). Retail price fixed for 56 new drugs and ceiling price of 3 formulations fixed during the 96th Authority Meeting held on 24.03.2022. Out of these Ceiling price for 1 formulation Framycetin Cream 0.5% and Retail price for 38 formulations were notified in April 2022.
- (ii). Inputs provided for India-US Trade Policy Forum- India's Non agricultural issues.
- (iii). Inputs provided on the recommendations of CEO Round Table meeting 7th edition of India Pharma 2022 & India Medical Device 2022 from 25th – 27th April, 2022.
- (iv). Request for Proposal (RFP) for conducting the study entitled as to study the drug pricing policies of different countries/ region and lessons learnt from these countries/ regions in terms of access to medicine at affordable prices was issued.
- (v). On the basis of Monitoring & Enforcement activities carried out by Enforcement Division, 35 Preliminary Notices (PNs) have been issued. Also, an amount of Rs. 50,198/- towards the overcharged amount has been received in 1 case.

D. Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

		at MRP V Crore an common	Value in Rs. d saving to man during tonth of	(As on 30		Suvidha Sanitary	-
April 2022	Cumulative	Sale	Saving	Medicines	Surgical	A	
111	8721 (As on 30.04.2022)	58.65 Crore (approx.)	352.00 Crore (approx.)	1616	250	1.01 (Crore)	1.95 Cr.

E. India Pharma 2022 & India Medical Devices 2022:

India Pharma 2022 & India Medical Devices 2022 held from 25th to 27th April 2022 in collaboration with FICCI and Invest India.

F. Status of PLI Schemes:

S. No.	Name of Scheme			No. of Applications approved in the month of February 22	approved till
1.		Round 1	215	0	41
	Scheme for Bulk Drug (Last EC Meeting held on	Round 2	24	08	08
	(Last EC Meeting held on 25.11.2021 on PLI Bulk Drugs)	Total	239	08	49
2.	Production Linked Incentive Scheme for Medical Device (Last	Round 1	28	0	13
	EC Meeting held on 25.11.2021	Round 2	14	08	08
	on Medical Devices)*		42	08	21
3.	Production Linked Incentive Sc Pharmaceuticals	cheme for	278	N/A	55

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of 'sanction for prosecution' pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhta Abhiyan (progress under Special Campaign):

(i) The requirement of monthly updation of the SCDPM Portal has been fulfilled by uploading the April month information made available by various Sections in the 2.0 version of the SCDPM Portal.

(ii) National Pharmaceutical Pricing Authority (NPPA): As part of the Swachhta Abhiyan, a special drive has been launched for identification of Bio-Medical wastes comprising of outdated, contaminated and discarded medicines. Since disposal of such Bio medical wastes requires expertise for their handling and facilities like Incinerator, Autoclave or Microwave System, the matter has been taken up with Lady Hardinge Medical College, New Delhi for making necessary arrangements for disposal of old and unused drugs.

(iii) Public Sector Undertakings:

(a) **IDPL:** Following activities were carried out under Swachhta Abhiyan in the month:

- i) Regular and dedicated cleaning drive of office premises and plant campuses.
- ii) To prevent spread of diseases; insecticide spray was carried out.
- iii) Regular cleaning of standing water to prevent mosquito breeding.
- iv) Maintenance of parks and removal of dead leaves.

(b) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL): As a routine practice, swachhta/cleaning activities are undertaken both at Corporate Office and factory daily. Company observes Swachhata Pakhwada annually during the month of September. As a part of Swachhata Pakhwada, Campaign on special activities like clearing old files/records, cleaning the entire surroundings of both Factory and Corporate Office are undertaken.

(c) Hindustan Antibiotics Limited (HAL): As per directives received from SCOPE & Department of Pharmaceuticals vide letter dated 22.12.2021, Swacchata Pakhwada will be observed from 1-15th September, 2022 in Hindustan Antibiotics Ltd.

This year HAL has observed Swachhta Pakhwada and Special drive on Swachhta from 1st October, 2021 to 15th October, 2021 & 1st October, 2021 to 31.10.2021 respectively. HAL has continued the same following the COVID guidelines and social distancing measures.

6. Status of Rationalization of Autonomous Bodies: Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Vacancy
1	Director/Deputy Secretary	1
2	Under Secretary	2
3	Principal Private Secretary	2

(ii) National Institute of Pharmaceutical Education & Research:

NIPER	Vacant Position	
NIPER- Raebareli	Director	

	NIPER-	Ahmedabad
--	--------	-----------

Director

NIPER - Hajipur, Director - Under Suspension

(iii) Public Sector Undertakings:

S.No.	Designation	Vacant Positions
1	Senior Manager	04
2	Deputy General Manager	03
3	General Manager	07
	Total	14

(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

(b) Hindustan Antibiotics Limited (HAL:

S.No.	Designation	Vacant Positions
1	CGM	2
2	GM	3
3	DGM	12
4	Manager	19
	Total	36

(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL):

S.No.	Designation	Vacant Positions
1	DGM/AGM	3
2	Sr. Manager	3
3	DGM (Marketing)	1
4	DGM(Finance)	1
	Total	8

(d) Indian Drugs & Pharmaceuticals Limited (IDPL): NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL): NIL

9. List of cases in which ACC directions have not been complied with:

NIL

10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

- (i) Pending at beginning of the month:- (9)
- (ii) Received during the month:- (2)
- (iii) Disposed of during the month:- (0)
- (iv) Pending at end of the month:- (11)
